Floatz logo

Entacapone

Multiple System Atrophy

Daniel ClaassenSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Multiple System Atrophy cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
Ath-434
Alterity Therapeutics
Phase 2B
Ioflupane
GE Healthcare
Phase 3B
Riluzole
King's College London
Phase 3B

View all 39 →

Same molecule, other indications

Entacapone is also rated in:

Parkinson diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
autonomic nervous system disorderActive
CCC
Indicative · Phase 1/2
54 / 100
View asset →
pure autonomic failureActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →